TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2367159

Group type: EXPERIMENTAL
Intervention: Intramuscular gamma-globulin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 758758

Group type: EXPERIMENTAL
Intervention: Intravenous acebutolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Saline solution
Number of subjects: 20
Study: 30842035

Group type: EXPERIMENTAL
Intervention: Socially Evaluated Cold Pressor Task (SECPT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Warm-water control condition
Number of subjects: 100
Study: 28730418

Group type: EXPERIMENTAL
Intervention: 1 μg IV low dose cosyntropin test
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 25 μg IM medium dose cosyntropin test
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 250 μg IM standard dose cosyntropin test (30 min)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 250 μg IM standard dose cosyntropin test (60 min)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Insulin tolerance test
Number of subjects: 22
Study: 26367388

Group type: EXPERIMENTAL
Intervention: CPOE
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control
Number of subjects: 36
Study: 23248256

Group type: EXPERIMENTAL
Intervention: Carboplatin and paclitaxel with sorafenib (CPS)
Number of subjects: 823

Group type: COMPARATOR
Intervention: Carboplatin and paclitaxel (CP)
Number of subjects: 823
Study: 20629805

Group type: EXPERIMENTAL
Intervention: Positive CBM training
Number of subjects: 82

Group type: COMPARATOR
Intervention: Negative CBM training
Number of subjects: 82
Study: 18751690

Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg twice daily) with rifampicin-based tuberculosis therapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Nevirapine (200 mg twice daily) without rifampicin-based tuberculosis therapy
Number of subjects: 53
Study: 17725475

Group type: EXPERIMENTAL
Intervention: Tidal breathing during sitting
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tidal breathing during right side‐lying
Number of subjects: 10
Study: 16126933

Group type: EXPERIMENTAL
Intervention: Heated humidifiers
Number of subjects: 369

Group type: COMPARATOR
Intervention: Heat and moisture exchanger filters
Number of subjects: 369
Study: 12461419

Group type: EXPERIMENTAL
Intervention: stavudine/lamivudine/indinavir
Number of subjects: 170

Group type: COMPARATOR
Intervention: zidovudine/lamivudine/indinavir
Number of subjects: 170
Study: 10496303

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir 450, 875, 1750 and 2625 mg once daily for 3 days
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Oral valganciclovir 900 mg/day
Number of subjects: 39
Study: 8768808

Group type: EXPERIMENTAL
Intervention: Red wine with 3,700 micrograms histamine/l
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Red wine with 200 micrograms histamine/l
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo (histamine-poor wine)
Number of subjects: 1
Study: 2015149

Group type: EXPERIMENTAL
Intervention: lignocaine 0.1 mg kg‐1
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: lignocaine 0.2 mg kg‐1
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: lignocaine 0.4 mg kg‐1
Number of subjects: 310

Group type: COMPARATOR
Intervention: no lignocaine
Number of subjects: 310
Study: 6258871

Group type: EXPERIMENTAL
Intervention: APE (adriamycin 35 mg/m2 IV D1 Q 3 weeks; procarbazine 60 mg/m2 PO D1-10 Q 3 weeks; VP16-213 130 mg/m2 IV D8, 15 Q 3 weeks)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: MOCC (methotrexate 15 mg/m2 IV or PO twice weekly D8-21 Q 3 weeks; Oncovin 1.5 mg/m2 IV D8, 15 Q 3 weeks; cyclophosphamide 600 mg/m2 IV D1 Q 3 weeks; CCNU 60 mg/m2 PO Q 6 weeks)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both regimens (APE and MOCC)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Alternate regimen after crossover
Number of subjects: 39

Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 39
Study: 31633520

Group type: EXPERIMENTAL
Intervention: High‐fidelity simulator
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional teaching model
Number of subjects: 59
Study: 27882595

Group type: EXPERIMENTAL
Intervention: Interactive hands-on experience
Number of subjects: 0

Group type: COMPARATOR
Intervention: Storybook
Number of subjects: 0
Study: 25930049

Group type: COMPARATOR
Intervention: Primary care-based treatment visit
Number of subjects: 2146

Group type: COMPARATOR
Intervention: Collaborative care visit
Number of subjects: 2146
Study: 24460645

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg once daily for 35 ± 4 days
Number of subjects: 7581

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg once daily for 10 ± 4 days then placebo up to day 35
Number of subjects: 7581

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7581
Study: 22832965

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) for 15 weeks
Number of subjects: 9
Study: 19299767

Group type: EXPERIMENTAL
Intervention: Arndt wire‐guided bronchial blocker (BB)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Cohen Flexi‐tip bronchial blocker (BB)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Fuji Uni‐blocker (BB)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Left‐sided double‐lumen tube (DLT)
Number of subjects: 104
Study: 17584267

Group type: EXPERIMENTAL
Intervention: ICD stress and shock management program (six-week format)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ICD stress and shock management program (one-day workshop format)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 16892580

Group type: EXPERIMENTAL
Intervention: Before hemodialysis
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: After hemodialysis
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 48

Group type: COMPARATOR
Intervention: Kidney graft recipients
Number of subjects: 48
Study: 12145118

Group type: EXPERIMENTAL
Intervention: Aerobic dance sessions
Number of subjects: 12

Group type: COMPARATOR
Intervention: Walking sessions
Number of subjects: 12
Study: 9690731

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg daily for 7 days
Number of subjects: 15

Group type: COMPARATOR
Intervention: Theophylline 250 mg on days 1, 2, 4 and 6
Number of subjects: 15
Study: 2622725

Group type: EXPERIMENTAL
Intervention: 3 sec. rate of digit presentation
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: 60‐dB sound-pressure level (SPL) of white masking noise at 1-sec. rate
Number of subjects: 123

Group type: COMPARATOR
Intervention: 70‐dB sound-pressure level (SPL) of white masking noise at 1-sec. rate
Number of subjects: 123

Group type: COMPARATOR
Intervention: 1 sec. rate of digit presentation
Number of subjects: 123
Study: 277678

Group type: EXPERIMENTAL
Intervention: Topical 2% sodium fluoride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined strontium and fluoride treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 25% strontium chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: 2% sodium fluoride
Number of subjects: 0
Study: 31163551

Group type: EXPERIMENTAL
Intervention: Adrenalin saline local injection (5 ml, concentration 1:200,000)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no injection)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups (post-surgery)
Number of subjects: 50
Study: 29442057

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 960

Group type: COMPARATOR
Intervention: Fentanyl (Control)
Number of subjects: 960
Study: 25271172

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) metronidazole, 15 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral metronidazole
Number of subjects: 12

Group type: COMPARATOR
Intervention: Comparison between 1-2.5 days and 10-12 days of age
Number of subjects: 12
Study: 22711058

Group type: EXPERIMENTAL
Intervention: Remote assessment via videoconferencing
Number of subjects: 10

Group type: COMPARATOR
Intervention: In-person assessment
Number of subjects: 10
Study: 21335973

Group type: EXPERIMENTAL
Intervention: Aromatherapy with melissa oil
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 20027852

Group type: EXPERIMENTAL
Intervention: Whole-body vibration session (frequencies 35-40 Hz) for 30 min before the dive
Number of subjects: 14

Group type: COMPARATOR
Intervention: No vibration (control dive)
Number of subjects: 14
Study: 16952493

Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg twice daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg 3 times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 14973303

Group type: EXPERIMENTAL
Intervention: Quinidine (600 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intravenous fentanyl (2.5 microg/kg)
Number of subjects: 12
Study: 11914029

Group type: EXPERIMENTAL
Intervention: rhGH administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 0
Study: 9136788

Group type: EXPERIMENTAL
Intervention: Standardized patient intervention during the surgery clerkship
Number of subjects: 153
Study: 8123395

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 16
Study: 3565116

Group type: EXPERIMENTAL
Intervention: Advised in advance of the biological test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live explanation and demonstration of the biological testing procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Advised of the testing procedure only after completing their questionnaire
Number of subjects: 0
Study: 28917618

Group type: EXPERIMENTAL
Intervention: Gap Balancing (GB)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Measured Resection
Number of subjects: 103
Study: 27742627

Group type: EXPERIMENTAL
Intervention: Modified STarT Back Tool score
Number of subjects: 2969
Study: 24886786

Group type: EXPERIMENTAL
Intervention: Life Shift SBIRT intervention
Number of subjects: 700

Group type: COMPARATOR
Intervention: Shift Gears attention-placebo control
Number of subjects: 700
Study: 23525432

Group type: EXPERIMENTAL
Intervention: urocortin 2 (3.6 to 120 pmol/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: urocortin 3 (1.2 to 36 nmol/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: substance P (2 to 8 pmol/min)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: urocortin 2 and urocortin 3 in the presence of all 3 inhibitors (aspirin, fluconazole, L‐NMMA)
Number of subjects: 18
Study: 20870121

Group type: EXPERIMENTAL
Intervention: Tissue-saving photorefractive keratectomy (PRK) using Zyoptix algorithm
Number of subjects: 93

Group type: COMPARATOR
Intervention: Conventional photorefractive keratectomy (PRK) using PlanoScan algorithm
Number of subjects: 93
Study: 19064853

Group type: EXPERIMENTAL
Intervention: Intensive therapy aimed at near-normal glycemia
Number of subjects: 1211

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 1211
Study: 16608158

Group type: EXPERIMENTAL
Intervention: Strong therapeutic alliance
Number of subjects: 785

Group type: COMPARATOR
Intervention: Low therapeutic alliance
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: High self-efficacy
Number of subjects: 785

Group type: EXPERIMENTAL
Intervention: Therapeutic alliance (general)
Number of subjects: 785
Study: 12918543

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antiarrhythmic drugs (AAD)
Number of subjects: 0
Study: 12145792

Group type: EXPERIMENTAL
Intervention: Combination endoscopic therapy (with epinephrine injection, shaving down the clot with cold guillotining, and bipolar coagulation on the underlying stigmata)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 32
Study: 9651664

Group type: EXPERIMENTAL
Intervention: celiprolol (beta 1‐ and beta 2‐adrenoceptor partial agonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: propranolol (beta 1‐ and beta 2‐adrenoceptor antagonist)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: atenolol (beta 1‐adrenoceptor antagonist)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7980716

Group type: EXPERIMENTAL
Intervention: 3 meals/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 9 meals/day
Number of subjects: 16
Study: 2646846

Group type: EXPERIMENTAL
Intervention: Cimetidine (600 mg p.o. + 200 mg i.m.)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg p.o. + 50 mg i.m.)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study: 31909412

Group type: EXPERIMENTAL
Intervention: Lifestyle Africa intervention delivered by community health workers (CHWs) through video-assisted sessions and supplemented with text messages
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Lifestyle Africa intervention
Number of subjects: 200
Study: 31053989

Group type: EXPERIMENTAL
Intervention: Orantinib
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Orantinib (BCLC-B subgroup)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Placebo (BCLC-B subgroup)
Number of subjects: 432
Study: 28525821

Group type: EXPERIMENTAL
Intervention: CBT and exercise
Number of subjects: 54

Group type: COMPARATOR
Intervention: CBT only
Number of subjects: 54
Study: 26415812

Group type: EXPERIMENTAL
Intervention: Wenxin Keli
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 23900661

Group type: EXPERIMENTAL
Intervention: 10 years of lead time in full health preceding 5 years of unhealthy time (standard)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5 years of lead time preceding 5 years of unhealthy time (experimental)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 10 years of lead time and 5 years of unhealthy time, presented with a visual aid (experimental)
Number of subjects: 2
Study: 21312188

Group type: EXPERIMENTAL
Intervention: Pulsed electrical stimulation (PES)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 19815286

Group type: EXPERIMENTAL
Intervention: Educational video, review of barriers, regular phone call reminders, audible and visible reminders on DA devices
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard instructions to take drops as prescribed with no additional intervention
Number of subjects: 66
Study: 16711274

Group type: EXPERIMENTAL
Intervention: AR splint (Group I)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SVED and MORA splints (Group II)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control Group (no treatment)
Number of subjects: 50
Study: 15002083

Group type: EXPERIMENTAL
Intervention: Calcium carbonate 500 mg twice daily for 2 weeks
Number of subjects: 0
Study: 11708573

Group type: EXPERIMENTAL
Intervention: Policosanol 5 mg/day for 8 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Policosanol 10 mg/day for the next 8 weeks
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Policosanol
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 9144826

Group type: EXPERIMENTAL
Intervention: Interventions for preventing aggression including a protocol for talking to patients, discussing treatment goals, explaining locked door policies, providing staff meeting schedules, and clarifying appointment procedures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interventions for preventing aggression
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control wards (no specific interventions implemented)
Number of subjects: 0
Study: 8198303

Group type: EXPERIMENTAL
Intervention: Technique 2 (added an abdominal strap to the control technique)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control technique (standard strapping without abdominal strap)
Number of subjects: 19
Study: 3309074

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg) administered 30 min before amphotericin B
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30663869

Group type: EXPERIMENTAL
Intervention: 4 mg baricitinib
Number of subjects: 3492

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: 2 mg baricitinib
Number of subjects: 3492

Group type: EXPERIMENTAL
Intervention: All-bari-RA (all doses)
Number of subjects: 3492
Study: 27846612

Group type: EXPERIMENTAL
Intervention: High-dose plerixafor (480 μg/kg)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Conventional-dose plerixafor (240 μg/kg)
Number of subjects: 23
Study: 25272318

Group type: EXPERIMENTAL
Intervention: PRP plus 2 ranibizumab injections
Number of subjects: 30

Group type: COMPARATOR
Intervention: PRP alone
Number of subjects: 30
Study: 23672633

Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 21446219

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) therapy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral anti-oxidant treatment (vitamin C-100 mg BD and vitamin E-400 IU BD) for 45 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (healthy normal subjects)
Number of subjects: 20
Study: 18997671

Group type: EXPERIMENTAL
Intervention: Culturally adapted weight loss program
Number of subjects: 213

Group type: COMPARATOR
Intervention: General health control group
Number of subjects: 213
Study: 16786406

Group type: EXPERIMENTAL
Intervention: Gruesome photographs
Number of subjects: 0

Group type: COMPARATOR
Intervention: No photographs (neutral evidence)
Number of subjects: 0
Study: 15373936

Group type: EXPERIMENTAL
Intervention: Fumarate tablet (120 mg dimethylfumarate and 95 mg calcium‐monoethylfumarate) taken in the fasted state
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fumarate tablet taken after a standardized breakfast
Number of subjects: 10
Study: 11419825

Group type: EXPERIMENTAL
Intervention: Aspirin (81 mg every day or 325 mg every 3 days)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 9173339

Group type: EXPERIMENTAL
Intervention: Oral estrogen-progestin contraception
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 45
Study: 8282457

Group type: EXPERIMENTAL
Intervention: More than six sexual partners
Number of subjects: 257

Group type: EXPERIMENTAL
Intervention: Oral contraceptives for > 10 years
Number of subjects: 257
Study: 2881568

Group type: EXPERIMENTAL
Intervention: Pancuronium 0.1 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vecuronium 0.1 mg kg‐1
Number of subjects: 30
Study: 31895298

Group type: EXPERIMENTAL
Intervention: α‐lactalbumin (LA)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Collagen peptides (CP)
Number of subjects: 11
Study: 30375497

Group type: EXPERIMENTAL
Intervention: Characterisation of dissolved organic matter (DOM) using a novel liquid chromatography ‐mass spectrometry method
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Correlation of DOM composition with groundwater flow‐paths and regional mean temperature
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Assessment of the impact of groundwater geochemistry and climate on DOM composition
Number of subjects: 74
Study: 26545392

Group type: EXPERIMENTAL
Intervention: Gait training combined with compelled weight-shift therapy (experimental group, n=14)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Gait training alone (control group, n=14)
Number of subjects: 28
Study: 26106552

Group type: EXPERIMENTAL
Intervention: Postural motor adaptation in PwMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Functional connectivity in PwMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortico-cerebellar connectivity in PwMS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortico-striatal connectivity in PwMS
Number of subjects: 0
Study: 23114833

Group type: EXPERIMENTAL
Intervention: Acipimox (used before and during endurance exercise)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control conditions (no Acipimox)
Number of subjects: 2
Study: 20456839

Group type: EXPERIMENTAL
Intervention: Herbal medicine treatment plus Western medicine (group A)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Western medicine plus placebo (group B)
Number of subjects: 537
Study: 17360151

Group type: EXPERIMENTAL
Intervention: Enhanced physical activity (EPA) intervention
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 29
Study: 14744743

Group type: EXPERIMENTAL
Intervention: Raw cabbage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cooked cabbage
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Mustard
Number of subjects: 12
Study: 11846968

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg (kg body mass)(‐1))
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo capsule
Number of subjects: 9
Study: 9569951

Group type: EXPERIMENTAL
Intervention: HDF 100 ml/min
Number of subjects: 8
Study: 7850539

Group type: EXPERIMENTAL
Intervention: IRP with melphalan followed by wide excision (WE) and fasciotomy
Number of subjects: 97

Group type: COMPARATOR
Intervention: WE only
Number of subjects: 97
Study: 3289929

Group type: EXPERIMENTAL
Intervention: Iopamidol 150 mg I/ml
Number of subjects: 46

Group type: COMPARATOR
Intervention: Iopamidol 200 mg I/ml
Number of subjects: 46
Study: 29804486

Group type: COMPARATOR
Intervention: Continuous subcuticular sutures using vicryl 3/0
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Interrupted subcuticular suturing using vicryl 3/0
Number of subjects: 169
Study: 29580594

Group type: EXPERIMENTAL
Intervention: 10‐mL ice popsicle
Number of subjects: 208

Group type: COMPARATOR
Intervention: 10 mL of water at room temperature
Number of subjects: 208
Study: 27099232

Group type: EXPERIMENTAL
Intervention: Lean seafood diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Nonseafood diet
Number of subjects: 20
Study: 25130571

Group type: EXPERIMENTAL
Intervention: HM-derived cream supplement
Number of subjects: 78

Group type: COMPARATOR
Intervention: Standard feeding regimen (control)
Number of subjects: 78